PLX 2.04 ▲ 0.00% Live Trading Data - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Protalix BioTherapeutics ...

    AMEX: PLX · Real-Time Price · USD
    2.04
    0.00 (0.00%)
    At close: Sep 26, 2025, 3:59 PM
    2.05
    0.24%
    After-hours: Sep 26, 2025, 07:57 PM EDT
    0.00%
    Bid 2
    Market Cap 163M
    Revenue (ttm) 61.95M
    Net Income (ttm) 6.28M
    EPS (ttm) 0.09
    PE Ratio (ttm) 22.72
    Forward PE 3.72
    Analyst Strong Buy
    Dividends n/a
    Ask 2.14
    Volume 368,287
    Avg. Volume (20D) 844,925
    Open 2.05
    Previous Close 2.04
    Day's Range 2.00 - 2.08
    52-Week Range 0.99 - 3.10
    Beta -0.23
    Ex-Dividend Date n/a

    About PLX

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol PLX
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for PLX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Next Earnings Release

    Protalix BioTherapeutics Inc. is scheduled to release its earnings on Nov 13, 2025, before market opens.
    Analysts project revenue of ... Unlock content with Pro Subscription
    4 months ago
    -40.48%
    Protalix BioTherapeutics shares are trading lower ... Unlock content with Pro Subscription
    6 months ago
    +9.38%
    Protalix BioTherapeutics shares are trading higher after the company reported a FY 2024 GAAP EPS beat.
    news image

    2 weeks ago · accessnewswire.com

    Protalix BioTherapeutics to Present at Investor Summit Virtual

    CARMIEL, ISRAEL / ACCESS Newswire / September 11, 2025 / Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of...

    news image

    1 month ago · seekingalpha.com

    Protalix: Speculative Buy On Promising Plant-Cell Platform And Elfabrio Ramp

    Protalix BioTherapeutics uses a plant-cell approach with ProCellEx. This has given it two approved ERTs plus PRX-115 and PRX-119. Its main focus is on a growing rare-disease pipeline. The main value d...

    news image

    1 month ago · seekingalpha.com

    Protalix BioTherapeutics, Inc. (PLX) Q2 2025 Earnings Call Transcript

    Protalix BioTherapeutics, Inc. (NYSE:PLX ) Q2 2025 Earnings Call August 14, 2025 8:30 AM ET Company Participants Dror Bashan - President, CEO & Director Eyal Rubin - Senior VP, CFO, Treasurer & Corpor...

    news image

    1 month ago · proactiveinvestors.com

    Protalix BioTherapeutics lifts revenue on strong Elfabrio demand

    Protalix Biotherapeutics Inc (NYSE-A:PLX) reported higher quarterly revenue and reaffirmed its long-term growth outlook on Thursday, pointing to expanding demand for its Fabry disease treatment Elfabr...

    news image

    2 months ago · proactiveinvestors.com

    Protalix BioTherapeutics welcomes new finance chief

    Protalix BioTherapeutics Inc (NYSE-A:PLX) has announced the appointment of Gilad Mamlok as senior vice president and chief financial officer, succeeding Eyal Rubin. Mamlok has already joined the compa...

    news image

    2 months ago · proactiveinvestors.com

    Protalix BioTherapeutics joins Russell 3000 and 2000 indexes following annual reconstitution

    Protalix Biotherapeutics Inc (NYSE-A:PLX) announced that it has been added to the Russell 3000 and Russell 2000 Indexes, effective after the US market closed on Friday, June 27.  The inclusion follows...

    Add to Watchlist